In the News

Multiple media sources are reporting on new data from the CDC revealing a substantial increase in the suicide rate in the United States between 1999...

A change.org petition out of the United Kingdom is addressing the extreme difficulty faced by people who attempt to taper off of antidepressants and...

A new study explores how people manage to discontinue antipsychotic medication and examines how social supports may improve outcomes.

The US FDA has issued a new warning for the atypical antipsychotic Olanzapine, also known by the brand names Zyprexa and Symbyax. The agency...

The UK Times reports that pharmaceutical companies are actively lobbying to limit the release of clinical trial data to the public. Rather than limiting results and data to medical journals, new transparency initiatives are pushing for making the information publically available. The push for transparency comes in the wake of the reanalysis of the Study 329 data on paroxetine (marketed as Seroxat and Paxil), which found that the industry study had misconstrued its results.

In an open letter to all US presidential candidates published Thursday in the BMJ, a group of global health care experts assert that current research regulations allow drug companies to publish incomplete and misleading results. They ask the candidates to declare whether they support improved transparency measures that would make data on drug studies publically available and open to scrutiny.

Primary care clinicians and mental health providers face a particular set of challenges when treating individuals with chronic pain. These problems are compounded by...

Researchers from the State University of New York at Buffalo (UB) found that antidepressants weaken bone growth which can disrupt procedures like tooth implants....

Ayahuasca found to be effective in treating moderate to severe depression in low-income population.

The warning label for the antidepressant Cymbalta downplayed the risks of withdrawal effects, according to consumer lawsuits being filed in courts across the country. “An estimated 44% to 78% of people who stop taking Cymbalta (also known as duloxetine) will suffer from withdrawal reactions,” yet the warning label “suggests the risk is greater than or equal to 1%.”

A new study has found that antidepressants are ineffective for reducing suicide attempts. Researchers report that the risk of suicide is particularly high in the first month after starting an antidepressant.

A review article published in the International Journal of Neuropsychopharmacology summarizes the latest research on the role that microbiota in the gut play in...

The study finds that curcumin may be as efficacious as antidepressant medications, particularly for atypical depression

Analysis of longitudinal data from 2000-2014 demonstrate mortality gap is widening between persons with a diagnosis of bipolar or schizophrenia compared to the general population

Review of a new mixed depression guideline reveals financial bias of guideline developers and lack of evidence supporting recommendations for prescribing of antipsychotics.

This month’s issue of JAMA Psychiatry ran an editorial commenting on recent research revealing that the majority of youth prescribed antipsychotics have not been diagnosed with a mental disorder.

An increase in suicidal thoughts is a known and serious side-effect for various types of antidepressants. Recent studies suggest that there may be some...

New research counters the long-held assumption that a longer duration of untreated psychosis is associated with worse outcomes.

Many experts expressed concern when the rate of antipsychotic prescriptions to children in foster care showed a rapid increase, peaking in 2008, and new recommendations and policies have tried to curb the use of these drugs. While the rate has plateaued, a new study points out that the “new normal” prescription levels are still dangerously high. The data reveals that almost one in ten children in foster care are currently being prescribed antipsychotic drugs with dangerous side-effects, many for diagnoses like ‘ADHD’ and disruptive behavior.

Clinical trials also consistently fail to measure and report long-term harmful effects.

Antipsychotics are currently the predominant treatment for individuals diagnosed with schizophrenia, but there is an accumulating body of research that links the use of these drugs to structural abnormalities in the brain. A recent meta-analysis suggests that gray matter loss in the brain may depend on the dose and class of the antipsychotic.

Few DTC drug advertisements fully adhere to FDA guidelines, the overall quality of information provided in DTC advertisements is low, and some advertisements market off-label indications.

Taking antidepressant or benzodiazepine medications increases the risks that a person will commit a homicide, according to a study from Finland published in a World Psychiatry letter.

Due to the thickness of the scalp and skull, transcranial electrical stimulation (TES) is incapable of targeting networks of neurons in the brain.

Corruption of pharmaceutical industry sponsored clinical trials identified as a “major obstacle” facing evidence-based medicine.